Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Prevalentie en mortaliteit van COVID-19 bij patiënten met kanker
okt 2020 | Leukemie, Lymfoom, MM